Works matching DE "VEMURAFENIB"

Results: 131

Preparation and characterization of vemurafenib microemulsion based hydrogel using surface active ionic liquid.

Published in:

Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e111178

By:

Neamah, Mohammed Jasim;
Muhammed Al-Akkam, Entidhar Jasim

Publication type:

Article

Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib‐Induced Renal Tubular Toxicity.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2025, v. 136, n. 4, p. 1, doi. 10.1111/bcpt.70015

By:

Sanagawa, Akimasa;
Takase, Hiroshi

Publication type:

Article

Effect of antioxidants coenzyme Q10 and β-carotene on the cytotoxicity of vemurafenib against human malignant melanoma.

Published in:

Oncology Letters, 2021, v. 21, n. 3, p. N.PAG, doi. 10.3892/ol.2021.12469

By:

Hu, Changkun;
Huang, Yuan;
Luo, Peixiao;
Yang, Yixin

Publication type:

Article

Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.

Published in:

Oncology Letters, 2018, v. 15, n. 3, p. 3904, doi. 10.3892/ol.2018.7770

By:

Zhi, Jie;
Li, Zhongxin;
Lv, Jian;
FENg, Bo;
Yang, Donghai;
Xue, Liang;
Zhao, Zhaolong;
Zhang, Yanni;
Wu, Jianhua;
Jv, Yingchao;
Jia, Yitao

Publication type:

Article

Efficacy of vemurafenib in a heavy smoker with BRAF-mutated lung adenocarcinoma: A case report and literature review.

Published in:

Molecular & Clinical Oncology, 2018, v. 9, n. 4, p. 472, doi. 10.3892/mco.2018.1691

By:

Liu, Xue;
Fang, Xuefeng;
Hu, Hanguang;
Fu, Xianhua;
Chen, Ying;
Yuan, Ying

Publication type:

Article

BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells.

Published in:

Metabolites (2218-1989), 2021, v. 11, n. 11, p. 777, doi. 10.3390/metabo11110777

By:

Karki, Prashant;
Sensenbach, Shayne;
Angardi, Vahideh;
Orman, Mehmet A.

Publication type:

Article

Retraction Note: Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma.

Published in:

2024

By:

Almajidi, Yasir Q.;
Maraie, Nidhal K.;
Raauf, Ayad M. R.

Publication type:

Correction Notice

Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma.

Published in:

Applied Nanoscience, 2023, v. 13, n. 4, p. 2845, doi. 10.1007/s13204-021-02158-y

By:

Almajidi, Yasir Q.;
Maraie, Nidhal K.;
Raauf, Ayad M. R.

Publication type:

Article

Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.

Published in:

Pediatric Hematology & Oncology, 2023, v. 40, n. 1, p. 86, doi. 10.1080/08880018.2022.2072986

By:

Mohapatra, Debabrata;
Gupta, Aditya Kumar;
Haldar, Partha;
Meena, Jagdish Prasad;
Tanwar, Pranay;
Seth, Rachna

Publication type:

Article

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 5345, doi. 10.2147/OTT.S325208

By:

del Carmen Álamo, Mª;
Ochenduszko, Sebastian;
Crespo, Guillermo;
Corral, Mónica;
Oramas, Juana;
Sancho, Pilar;
Medina, Javier;
Garicano, Fernando;
López, Pedro;
Balea, Begoña Campos;
Garzotto, Analia Rodríguez;
Muñoz-Couselo, Eva

Publication type:

Article

Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 4905, doi. 10.2147/OTT.S245531

By:

Liu, Can;
He, Siqi;
Zhang, Jianfei;
Li, Shiyan;
Chen, Jian;
Han, Chaofei

Publication type:

Article

Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability.

Published in:

OncoTargets & Therapy, 2018, v. 11, p. 8293, doi. 10.2147/OTT.S183311

By:

Li, Min;
Yang, Ying

Publication type:

Article

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.

Published in:

PLoS ONE, 2018, v. 13, n. 3, p. 1, doi. 10.1371/journal.pone.0195956

By:

Ladds, Marcus J. G. W.;
Pastor-Fernández, Andrés;
Popova, Gergana;
van Leeuwen, Ingeborg M. M.;
Eng, Kai Er;
Drummond, Catherine J.;
Johansson, Lars;
Svensson, Richard;
Westwood, Nicholas J.;
McCarthy, Anna R.;
Tholander, Fredrik;
Popa, Mihaela;
Lane, David P.;
McCormack, Emmet;
McInerney, Gerald M.;
Bhatia, Ravi;
Laín, Sonia

Publication type:

Article

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.

Published in:

PLoS ONE, 2018, v. 13, n. 2, p. 1, doi. 10.1371/journal.pone.0191264

By:

Joshi, Sandeep S.;
Jiang, Shunlin;
Unni, Emmanual;
Goding, Stephen R.;
Fan, Tao;
Antony, Paul A.;
Hornyak, Thomas J.

Publication type:

Article

A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?

Published in:

International Journal of Rheumatic Diseases, 2017, v. 20, n. 3, p. 398, doi. 10.1111/1756-185X.12396

By:

Babacan, Taner;
Türkbeyler, Ibrahim Halil;
Balakan, Ozan;
Pehlivan, Yavuz;
Suner, Ali;
Kısacık, Bunyamin

Publication type:

Article

Xanthohumol Sensitizes Melanoma Cells to Vemurafenib by Lowering Membrane Cholesterol and Increasing Membrane Fluidity.

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 5, p. 2290, doi. 10.3390/ijms26052290

By:

Devinat, Marine;
Thevenard-Devy, Jessica;
Ghilane, Fatiha;
Devy, Jerome;
Chazee, Lise;
Terryn, Christine;
Duca, Laurent;
Devarenne-Charpentier, Emmanuelle;
El Btaouri, Hassan

Publication type:

Article

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.

Published in:

Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y

By:

Corrales, Eyleen;
Levit-Zerdoun, Ella;
Metzger, Patrick;
Mertes, Ralf;
Lehmann, Ariane;
Münch, Julia;
Lemke, Steffen;
Kowar, Silke;
Boerries, Melanie

Publication type:

Article

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.

Published in:

Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00989-y

By:

Corrales, Eyleen;
Levit-Zerdoun, Ella;
Metzger, Patrick;
Mertes, Ralf;
Lehmann, Ariane;
Münch, Julia;
Lemke, Steffen;
Kowar, Silke;
Boerries, Melanie

Publication type:

Article

Suppression of exosomal hsa_circ_0001005 eliminates the Vemurafenib resistance of melanoma.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5921, doi. 10.1007/s00432-022-04434-y

By:

Wang, Xicheng;
Cheng, Qiong

Publication type:

Article

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement.

Published in:

2023

By:

Wang, Xiaomeng;
Cao, Jie;
Du, Weijiao;
Ma, Wenchao;
Meng, Bin;
Cao, Shui

Publication type:

Case Study

Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.

Published in:

Clinical Case Reports, 2017, v. 5, n. 5, p. 694, doi. 10.1002/ccr3.911

By:

Matsuo, Toshihiko;
Yamasaki, Osamu

Publication type:

Article

SERPINB8 and furin regulate ITGAX expression and affect the proliferation and invasion of melanoma cells.

Published in:

Experimental Dermatology, 2023, v. 32, n. 1, p. 24, doi. 10.1111/exd.14677

By:

Ni, Li;
Li, Pin;
Li, Mingming;
Huang, Shuhong;
Dang, Ningning

Publication type:

Article

Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 1, p. 39, doi. 10.1002/cpdd.822

By:

Zhang, Weijiang;
Mathisen, Michael;
Goodman, Grant R.;
Forbes, Harper;
Song, Yuyao;
Bertran, Enric;
Demidov, Lev;
Shin, Sang Joon

Publication type:

Article

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation–Positive Malignancies.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 5, p. 651, doi. 10.1002/cpdd.788

By:

Zhang, Weijiang;
McIntyre, Christine;
Riehl, Todd;
Forbes, Harper;
Bertran, Enric;
Choi, Hye Jin;
Lee, Dae Ho;
Lee, Jeeyun

Publication type:

Article

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 4, p. 496, doi. 10.1002/cpdd.773

By:

Zhang, Weijiang;
Colburn, Dawn;
Simmons, Brian;
Papai, Zsuzsanna;
Bertran, Enric;
Schadt, Simone;
Husser, Christophe;
Forbes, Harper;
Roethlisberger, Dieter;
Hartung, Thomas

Publication type:

Article

Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 837, doi. 10.1002/cpdd.643

By:

Zhang, Weijiang;
McIntyre, Christine;
Forbes, Harper;
Gaafar, Rabab;
Kohail, Hanaa;
Beck, J. Thaddeus;
Plestina, Stjepko;
Bertran, Enric;
Riehl, Todd

Publication type:

Article

Erdheim-Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes.

Published in:

Orbit, 2023, v. 42, n. 3, p. 233, doi. 10.1080/01676830.2022.2087232

By:

Park, Ji Kwan;
Huang, Laura C.;
Kossler, Andrea L.

Publication type:

Article

First Experiences With the Use of Targeted and Immunotherapy in the Treatment of Cutaneous Melanoma: a Single Centre Experience.

Published in:

Scripta Medica, 2022, v. 53, n. 1, p. 29, doi. 10.5937/scriptamed53-35184

By:

Berendika, Jelena;
Jungić, Saša;
Tubić, Biljana;
Rakita, Ivanka;
Vještica, Milka;
Đokanović, Dejan;
Gojković, Zdenka;
Mirčeta, Nikolina;
Petković, Sanja;
Peković, Vanda Marković

Publication type:

Article

Analysis of Survival at Metastatic Melanoma Patients Treated with Vemurafenib - a Three Year Single Institution Study.

Published in:

Scripta Medica, 2018, v. 49, n. 2, p. 126, doi. 10.7251/SCMED1802126G

By:

Gojković, Zdenka;
Đokanović, Dejan;
Jakovljević, Branislava;
Maksimović, Siniša;
Jungić, Saša;
Rakita, Ivanka;
Vještica, Milka;
Rašeta, Radmila;
Vranješ, Živko;
Štrbac, Marina

Publication type:

Article

A case of bilateral uveitis in a patient treated with vemurafenib.

Published in:

Oman Journal of Ophthalmology, 2022, v. 15, n. 3, p. 431, doi. 10.4103/ojo.ojo_240_21

By:

Mehmet, Aysel;
Mikropoulou, Athanasia Maria;
Panagiotopoulou, Eirini-Kanella;
Konstantinidis, Aristeidis;
Labiris, Georgios

Publication type:

Article

Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.

Published in:

Annals of Medicine, 2021, v. 53, n. 1, p. 1537, doi. 10.1080/07853890.2021.1966085

By:

Tang, Xue;
Gao, Ju;
Ma, Zhi-gui;
Guo, Xia;
Li, Qiang;
Wan, Zhi;
Sun, Jing-jing

Publication type:

Article

Resistance mechanism of the oncogenic β3‐αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.

Published in:

Chemical Biology & Drug Design, 2019, v. 93, n. 2, p. 177, doi. 10.1111/cbdd.13399

By:

Niu, Yuzhen;
Zhang, Yan;
Yao, Xiaojun

Publication type:

Article

Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenib.

Published in:

British Journal of Haematology, 2024, v. 204, n. 6, p. 2508, doi. 10.1111/bjh.19483

By:

Trambusti, Irene;
Pegoraro, Francesco;
Gaspari, Stefania;
Dell'Acqua, Fabiola;
Cellini, Monica;
Trizzino, Antonino;
Tondo, Annalisa;
Perrone, Anna;
Coniglio, Maria Luisa;
Guerrini, Renzo;
Barba, Carmen;
Sieni, Elena

Publication type:

Article

Pulmonary Erdheim-Chester disease successfully treated with vemurafenib.

Published in:

Annals of Hematology, 2024, v. 103, n. 2, p. 673, doi. 10.1007/s00277-023-05534-6

By:

Shen, Kai-ni;
Chang, Long;
Niu, Na;
Li, Jian;
Cao, Xin-xin

Publication type:

Article

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Published in:

Acta Neuropathologica Communications, 2025, v. 13, n. 1, p. 1, doi. 10.1186/s40478-025-01972-7

By:

Ainiwan, Yilamujiang;
Li, Haomin;
Zheng, Yongjia;
Wei, Songtao;
Peng, Junxiang;
Nie, Jing;
Mao, Chaofu;
Chen, Kunxiang;
Chen, Siyuan;
Liu, Ningyuan;
Li, Can;
Chen, Yan;
Qu, Shanqiang;
Wang, Yunji;
Zhou, Mingfeng;
Mao, Jian;
Mei, Fen;
Chen, Jingting;
Song, Qiancheng;
Qi, Songtao

Publication type:

Article

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics.

Published in:

Cancer Biology & Medicine, 2019, v. 16, n. 2, p. 247, doi. 10.20892/j.issn.2095-3941.2018.0375

By:

Grahovac, Jelena;
Srdić-Rajić, Tatjana;
Santibañez, Juan Francisco;
Pavlović, Marijana;
Čavić, Milena;
Radulović, Siniša

Publication type:

Article

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1395378

By:

Samoylenko, Igor V.;
Kolontareva, Yulia M.;
Kogay, Ekaterina V.;
Zhukova, Natalia V.;
Utyashev, Igor A.;
Ivannikov, Mikhail E.;
Menshikov, Konstantin V.;
Zinkevich, Maxim V.;
Orlova, Kristina V.;
Vakhabova, Yulia V.;
Volkonsky, Mikhail V.;
Beliaeva, Natalia A.;
Butkov, Ivan I.;
Karabina, Elena V.;
Moskovkina, Tatyana L.;
Moshkova, Kseniya A.;
Plishkina, Olga V.;
Sychev, Vitaliy D.;
Cheplukhova, Oxana S.;
Chernova, Vera V.

Publication type:

Article

BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report.

Published in:

2024

By:

Ngelangel, Corazon A.;
Sy, Florge Francis

Publication type:

Case Study

Od mutacji do leku.

Published in:

Advances in Biochemistry / Postepy Biochemii, 2023, v. 69, n. 3, p. 1, doi. 10.18388/pb.2021_498

By:

Wnuk, Jan;
Wilanowski, Tomasz

Publication type:

Article

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Published in:

Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04391-1

By:

Dummer, Reinhard;
Welti, Michèle;
Ramelyte, Egle

Publication type:

Article

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.

Published in:

Pathology & Oncology Research, 2023, p. 1, doi. 10.3389/pore.2023.1611378

By:

Ferenczi, Kata;
Nagy, Zsófia Flóra;
Istenes, Ildikó;
Eid, Hanna;
Bödör, Csaba;
Timár, Botond;
Demeter, Judit

Publication type:

Article

B-Raf inhibitor vemurafenib counteracts sulfur mustard-induced epidermal impairment through MAPK/ERK signaling.

Published in:

Drug & Chemical Toxicology, 2023, v. 46, n. 2, p. 226, doi. 10.1080/01480545.2021.2021927

By:

Xiao, Zhiyong;
Liu, Feng;
Cheng, Junping;
Wang, Ying;
Zhou, Wenxia;
Zhang, Yongxiang

Publication type:

Article

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1182853

By:

Guzzetti, Carlotta;
Corno, Cristina;
Vergani, Elisabetta;
Mirra, Luca;
Ciusani, Emilio;
Rodolfo, Monica;
Perego, Paola;
Beretta, Giovanni L.

Publication type:

Article

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1100577

By:

Johnson, Anna E.;
Raju, Athul Raj;
Jacob, Aasems;
Hildebrandt, Gerhard C.

Publication type:

Article

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.

Published in:

Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, v. 35, n. 1, p. 39, doi. 10.5114/ada.2018.73163

By:

Rajczykowski, Marcin;
Kaminska-Winciorek, Grazyna;
Nowara, Elzbieta;
Samborska-Plewicka, Marzenna;
Giebel, Sebastian

Publication type:

Article

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib.

Published in:

Advances in Dermatology & Allergology / Postępy Dermatologii i Alergologii, 2018, v. 35, n. 1, p. 39, doi. 10.5114/ada.2018.73163

By:

Rajczykowski, Marcin;
Kaminska-Winciorek, Grazyna;
Nowara, Elzbieta;
Samborska-Plewicka, Marzenna;
Giebel, Sebastian

Publication type:

Article

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.

Published in:

Thyroid, 2022, v. 32, n. 3, p. 273, doi. 10.1089/thy.2021.0565

By:

Tchekmedyian, Vatche;
Dunn, Lara;
Sherman, Eric;
Baxi, Shrujal S.;
Grewal, Ravinder K.;
Larson, Steven M.;
Pentlow, Keith S.;
Haque, Sofia;
Tuttle, R. Michael;
Sabra, Mona M.;
Fish, Stephanie;
Boucai, Laura;
Walters, Jamie;
Ghossein, Ronald A.;
Seshan, Venkatraman E.;
Knauf, Jeffrey A.;
Pfister, David G.;
Fagin, James A.;
Ho, Alan L.

Publication type:

Article

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.

Published in:

PLoS ONE, 2017, v. 12, n. 8, p. 1, doi. 10.1371/journal.pone.0183498

By:

Zalesna, Izabela;
Osrodek, Marta;
Hartman, Mariusz L.;
Rozanski, Michal;
Sztiller-Sikorska, Malgorzata;
Niewinna, Karolina;
Nejc, Dariusz;
Czyz, Malgorzata

Publication type:

Article

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.

Published in:

Expert Review of Anticancer Therapy, 2022, v. 22, n. 1, p. 17, doi. 10.1080/14737140.2022.2017286

By:

Schmitt, Andreas M;
Dumas, Lucy;
Larkin, James

Publication type:

Article

Erdheim-Chester Disease With BRAF V600E Mutation and Central Diabetes Insipidus Successfully Treated With Glucocorticoid.

Published in:

JCEM Case Reports, 2023, v. 1, n. 2, p. 1, doi. 10.1210/jcemcr/luad014

By:

Imaizumi, Toshinori;
Daido, Hisashi;
Kato, Takehiro;
Yabe, Daisuke

Publication type:

Article